Cover Image

Intravenous artesunate for severe malaria in travelers, Europe

Multicenter trials in Southeast Asia have shown better survival rates among patients with severe malaria, particularly those with high parasitemia levels, treated with intravenous (IV) artesunate than among those treated with quinine. In Europe, quinine is still the primary treatment for severe mala...

Full description

Saved in:
Bibliographic Details
Main Authors: Zoller, Thomas (Author) , Junghanss, Thomas (Author) , Kapaun, Annette (Author) , Gjørup, Ida (Author) , Richter, Joachim (Author) , Hugo-Persson, Mats (Author) , Mørch, Kristine (Author) , Foroutan, Behruz (Author) , Suttorp, Norbert (Author) , Yürek, Salih (Author) , Flick, Holger (Author)
Format: Article (Journal)
Language:English
Published: May 2011
In: Emerging infectious diseases
Year: 2011, Volume: 17, Issue: 5, Pages: 771-777
ISSN:1080-6059
DOI:10.3201/eid1705.101229
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3201/eid1705.101229
Verlag, lizenzpflichtig, Volltext: https://wwwnc.cdc.gov/eid/article/17/5/10-1229_article
Get full text
Author Notes:Thomas Zoller, Thomas Junghanss, Annette Kapaun, Ida Gjørup, Joachim Richter, Mats Hugo-Persson, Kristine Mørch, Behruz Foroutan, Norbert Suttorp, Salih Yürek, and Holger Flick
Description
Summary:Multicenter trials in Southeast Asia have shown better survival rates among patients with severe malaria, particularly those with high parasitemia levels, treated with intravenous (IV) artesunate than among those treated with quinine. In Europe, quinine is still the primary treatment for severe malaria. We conducted a retrospective analysis for 25 travelers with severe malaria who returned from malaria-endemic regions and were treated at 7 centers in Europe. All patients survived. Treatment with IV artesunate rapidly reduced parasitemia levels. In 6 patients at 5 treatment centers, a self-limiting episode of unexplained hemolysis occurred after reduction of parasitemia levels. Five patients required a blood transfusion. Patients with posttreatment hemolysis had received higher doses of IV artesunate than patients without hemolysis. IV artesunate was an effective alternative to quinine for treatment of malaria patients in Europe. Patients should be monitored for signs of hemolysis, especially after parasitologic cure.
Item Description:Gesehen am 23.01.2023
Physical Description:Online Resource
ISSN:1080-6059
DOI:10.3201/eid1705.101229

Similar Items